Regeneron Pharmaceuticals Profit Margin

Regeneron Pharmaceuticals (REGN) currently reports a profit margin of 29.65% as of March 2026. That compares with 31.94% in the prior-year period — down 7.2% year over year. That is above the Healthcare sector average of 15.52%. Use the charts on this page to explore Regeneron Pharmaceuticals's profit margin history and peer comparisons.

Regeneron Pharmaceuticals's profit margin decreased from 31.94% to 29.65% — a 7.2% year-over-year decrease (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Regeneron Pharmaceuticals's profit margin of 29.65% is higher than the Healthcare sector average of 15.52%. That is roughly 91.0% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Regeneron Pharmaceuticals's current 29.65% should be judged against Healthcare norms (sector average: 15.52%) and against REGN's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of 29.65%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 15.52%. From there, open related valuation or income-statement pages for Regeneron Pharmaceuticals, and consider following REGN for alerts when major investors trade the stock.